The phase 3 RxFINE-Low trial will test whether some early-stage breast cancer patients can safely omit chemotherapy when they have low genomic risk but high anatomic risk. Enrolled patients will receive endocrine therapy plus a CDK4/6 inhibitor, aiming to preserve efficacy while reducing treatment burden for a molecularly selected group.